Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
120103725 | 12010372 | 5 | F | 20160125 | 20160720 | 20160205 | 20160803 | EXP | HU-PFIZER INC-2016058403 | PFIZER | 62.00 | YR | M | Y | 0.00000 | 20160803 | OT | HU | HU |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
120103725 | 12010372 | 1 | PS | SUTENT | SUNITINIB MALATE | 1 | Oral | 50 MG, 1X/DAY, ACCORDING TO 4/2 DOSING SCHEMA | 17500 | MG | Y | 21938 | 50 | MG | CAPSULE, HARD | QD |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
120103725 | 12010372 | 1 | Clear cell renal cell carcinoma |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
120103725 | 12010372 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
120103725 | 12010372 | Abdominal discomfort | |
120103725 | 12010372 | Abdominal distension | |
120103725 | 12010372 | Clear cell renal cell carcinoma | |
120103725 | 12010372 | Constipation | |
120103725 | 12010372 | Disease progression | |
120103725 | 12010372 | Palmar-plantar erythrodysaesthesia syndrome |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
120103725 | 12010372 | 1 | 20150210 | 20160518 | 0 |